{
    "id": "64178e15690f196b51000020",
    "question": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To determine if casimersen is effective for the treatment of Duchenne muscular dystrophy, we need to search for information about casimersen and its use in Duchenne muscular dystrophy. We can start by searching for casimersen in the provided documents and see if there is any information about its effectiveness in treating Duchenne muscular dystrophy.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "article-20747_1",
            "title": "Duchenne Muscular Dystrophy -- Continuing Education Activity",
            "content": "Objectives: Identify the etiology of Duchenne muscular dystrophy. Describe the presentation of a patient with Duchenne muscular dystrophy. Describe the management options available for Duchenne muscular dystrophy, as well as the limitations of current management options. Explain interprofessional team strategies for improving care coordination and communication to advance the treatment of Duchenne muscular dystrophy and improve outcomes. Access free multiple choice questions on this topic."
        },
        {
            "id": "article-25401_24",
            "title": "Muscular Dystrophy -- Epidemiology",
            "content": "Duchenne muscular dystrophy is the most common type of muscular dystrophy\u00a0observed in children, affecting approximately 1 in every 3,500 to 5,000 male births worldwide. Primarily affecting boys,\u00a0the onset of Duchenne muscular dystrophy typically occurs between the ages of 3 and 5 years.\u00a0The condition is progressive and ultimately fatal, with most individuals with Duchenne muscular dystrophy surviving into their\u00a0late teens or early 20s."
        },
        {
            "id": "article-25388_8",
            "title": "Physiology, Muscle -- Clinical Significance",
            "content": "Muscular dystrophy is a progressive genetic myopathy, which leads to degeneration of the normal anatomy and physiology of skeletal muscle cells. The complete or partial absence of the dystrophin protein is the pathologic mechanism of both Becker and Duchenne muscular dystrophy. Dystrophin is a protein that is associated with the filaments of skeletal muscle. Dystrophin provides structure and support to the sarcolemma of the monofilament. The lack of dystrophin protein leads to damage in the supporting sarcolemma, weakness, and eventual atrophy of healthy muscle fibers.\u00a0Duchenne\u00a0muscular dystrophy affects up to 1 in 3600 boys, making it the highest incidence\u00a0among the types of muscular dystrophies. Many with\u00a0Duchenne\u00a0have a low life expectancy because there is currently\u00a0no treatment available. Management of these disorders is purely supportive. The most common cause of death in these individuals is cardiorespiratory failure. [6]"
        },
        {
            "id": "Pediatrics_Nelson_3857",
            "title": "Pediatrics_Nelson",
            "content": "With prompt treatment and respiratory and supportive care, the prognosis is good. Muscular dystrophies are a group of genetic muscle diseases characterized by progressive myofiber degeneration and the gradual replacement of muscle by fibrotic tissue. Duchenne muscular dystrophy is the most common muscular dystrophy and one of the most common genetic disorders of childhood. Duchenne muscular dystrophy is an X-linked disorder (Xp21) affecting approximately 1 in 3500 boys and resulting from a gene mutation of dystrophin. Becker muscular dystrophy is an allelic disorder associated with more mild symptoms; its mutations at least partially preserve the function of the resulting gene product. Available @ StudentConsult.com"
        },
        {
            "id": "article-20747_0",
            "title": "Duchenne Muscular Dystrophy -- Continuing Education Activity",
            "content": "Unfortunately, Duchenne muscular dystrophy (DMD) is not only one of the most severe forms of inherited muscular dystrophies but also the most common hereditary neuromuscular disease. Sadly, there is no known treatment modality that halts the progression of the disease; available treatment options are palliative. Affected patients usually die in their twenties due to respiratory muscle weakness or cardiomyopathy. Current therapy is centered on treatment with glucocorticoids and physiotherapy to prevent orthopedic complications. This activity illustrates the pathophysiology and current management options for DMD and highlights the role of the interprofessional team in caring for affected patients and families."
        },
        {
            "id": "article-25401_61",
            "title": "Muscular Dystrophy -- History and Physical -- Delayed motor milestones",
            "content": "Duchenne muscular dystrophy is usually\u00a0diagnosed in children at\u00a0around the age of 3\u00a0when parents\u00a0observe\u00a0slow motor development. [103] Clinical symptoms\u00a0commonly\u00a0emerge between 5 and 15 years, marked by developmental delays in sitting, standing, and walking. [103] Children affected by Duchenne muscular dystrophy often exhibit clumsiness, frequent falls, and difficulties climbing stairs. [103] In contrast, individuals with Becker muscular dystrophy remain ambulatory into their teens and early 20s, with the average age for wheelchair necessity reported as 25 in one study. [77] The key distinction is that patients with Becker dystrophy can walk beyond age 15,\u00a0while\u00a0those with Duchenne dystrophy typically use a wheelchair by age 12. [103]"
        },
        {
            "id": "article-25401_60",
            "title": "Muscular Dystrophy -- History and Physical -- Contractures",
            "content": "Duchenne muscular dystrophy leads to complications such as muscle weakness, contractures of the knees, hips, and other joints, and scoliosis. [100] The contractures and skeletal deformities that develop from facioscapulohumeral muscular dystrophy are less\u00a0frequent and less prominent than Duchenne muscular dystrophy. [101] Clinical findings like foot drop and depressed or absent muscle stretch reflexes may be present. [102]"
        },
        {
            "id": "article-25401_124",
            "title": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials",
            "content": "Radiation therapy (RT) has been studied as a potential treatment for muscular dystrophy, particularly in the context of Duchenne muscular dystrophy."
        },
        {
            "id": "article-25401_102",
            "title": "Muscular Dystrophy -- Evaluation",
            "content": "Western blot:\u00a0Duchenne dystrophy can\u00a0be diagnosed through\u00a0Western blot analysis of muscle biopsy specimens, revealing abnormalities in dystrophin proteins' quantity and molecular weight. In Becker muscular dystrophy, dystrophin levels\u00a0may appear normal on Western blot despite the abnormal protein, contrasting with significantly decreased dystrophin levels in individuals with Duchenne muscular dystrophy. [185]"
        },
        {
            "id": "article-25401_129",
            "title": "Muscular Dystrophy -- Prognosis",
            "content": "Duchenne muscular dystrophy\u00a0typically results in a life expectancy of\u00a0around 20 years,\u00a0with a fatal outcome\u00a0in 100% of cases. [210] Children\u00a0affected by Duchenne muscular dystrophy usually succumb to other pulmonary or cardiac causes,\u00a0with\u00a0death\u00a0occurring\u00a0in\u00a0the late teens. Only 25% live to age 21. [211] Walker-Warburg syndrome, the most severe congenital muscular dystrophy,\u00a0leads to death by\u00a01 year of age. [211] Becker dystrophy is associated with a reduced life expectancy, but most individuals survive into the fourth or fifth decade. [211] Life expectancy is average in patients with facioscapulohumeral dystrophy. [211]"
        },
        {
            "id": "Neurology_Adams_11436",
            "title": "Neurology_Adams",
            "content": "6. The distinctions, in the child or adolescent, between dystrophy and one of the congenital or metabolic myopathies are considered later in this chapter. Treatment of the Muscular Dystrophies There has, until recently, been no specific treatment for any of the muscular dystrophies. The physician is forced to stand by and witness the unrelenting progression of weakness and wasting. The various vitamins, amino acids, testosterone, and drugs, such as penicillamine, recommended in the past, have all proved to be ineffective. The administration of prednisone appears to slightly retard the tempo of progression of Duchenne dystrophy for a period of up to 3 years (Fenichel et al). The optimal dose is 0.75 mg/kg given daily, but it must often be reduced because of intolerable side effects (weight gain, behavioral and gastrointestinal disorders)."
        },
        {
            "id": "article-20747_4",
            "title": "Duchenne Muscular Dystrophy -- Etiology",
            "content": "Mutations in the dystrophin gene result in diseases known as dystrophinopathies, which encompass Duchenne muscular dystrophy, Becker muscular\u00a0dystrophy, and an intermediate form. Mutations result in a limited production of the dystrophin protein, which results in loss of the myofiber membrane integrity with repeated cycles of necrosis and regeneration. Fibrous connective tissue and fat progressively replace muscle, leading to clinical features."
        },
        {
            "id": "article-760_33",
            "title": "Physiology, Skeletal Muscle -- Pathophysiology -- Muscular Dystrophies",
            "content": "Muscular dystrophies include more than 30 inherited conditions that cause permanent muscle weakness. The two most common and well-known forms of muscular dystrophy include Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). Duchenne Muscular Dystrophy (DMD) is an X-linked inherited neuromuscular disorder caused by mutations in the dystrophin gene.\u00a0This disease is characterized by progressive muscle wasting and\u00a0weakness due to the absence of dystrophin protein that causes skeletal and cardiac muscle degeneration. DMD affects approximately 1 in 3,600 male births worldwide, with clinical signs absent at birth. The average age of diagnosis, and first appearance of symptoms, is around\u00a0the age of 4. DMD is a fast-progressing disease, with patients relying on a wheelchair and developing severe cardiomyopathy at approximately ten years of age. Death\u00a0typically occurs\u00a0due to cardiac and respiratory complications. [16]"
        },
        {
            "id": "article-26410_13",
            "title": "Secondary Osteoporosis -- Etiology -- Neuromuscular Diseases",
            "content": "Duchenne muscular dystrophy : an X-linked recessive progressive muscular disease resulting from mutations in the dystrophin gene. Boys with\u00a0Duchenne muscular dystrophy have a significantly higher risk for osteoporosis, with a prevalence of almost 20 to 60% in this population. [18]"
        },
        {
            "id": "article-20747_2",
            "title": "Duchenne Muscular Dystrophy -- Introduction",
            "content": "Duchenne muscular dystrophy (DMD) is one of the most severe forms of inherited muscular dystrophies. It is the most common hereditary neuromuscular disease and does not exhibit a predilection for any race or ethnic group. Mutations in the dystrophin gene lead to progressive muscle fiber degeneration and weakness. This weakness may present initially with difficulty in ambulation but progressively advances to such an extent that affected patients are unable to carry out activities of daily living and must use wheelchairs. Cardiac and orthopedic complications are common, and death usually occurs in the twenties due to respiratory muscle weakness or cardiomyopathy. Current therapy is centered on treatment with glucocorticoids and physiotherapy to prevent orthopedic complications. [1] [2] [3]"
        },
        {
            "id": "article-25401_66",
            "title": "Muscular Dystrophy -- History and Physical -- Gower sign",
            "content": "Muscular weakness\u00a0typically begins in the pelvic girdle, causing a \"waddling\" gait. [103] About 80% of cases exhibit calf muscle hypertrophy. [110] The pattern of muscle wasting\u00a0observed in Becker muscular dystrophy\u00a0closely mirrors\u00a0that of Duchenne disease, with prominent involvement of proximal muscles, particularly\u00a0in the lower extremities.\u00a0As the\u00a0condition\u00a0advances, weakness becomes more widespread. [111] In Duchenne muscular dystrophy, the\u00a0weakening progresses over the following years, resulting in the loss of ambulation\u00a0by 8 to 13."
        },
        {
            "id": "article-25401_29",
            "title": "Muscular Dystrophy -- Epidemiology -- Muscular dystrophy",
            "content": "Most common childhood muscular dystrophy:\u00a0Duchenne Most common adult muscular dystrophy:\u00a0Myotonic [47] Prevalence of muscular dystrophy (general population):\u00a016\u00a0to 25.1 per 100,000 [48] [49] Frequency of muscular dystrophy (general population): 1 per 3,000\u00a0to 8,000 [50] [51] Incidence of muscular dystrophy (male births):\u00a01 per 5,000 or 200 per 1,000,000 [52]"
        },
        {
            "id": "article-22334_35",
            "title": "Glycogen Storage Disease -- Differential Diagnosis",
            "content": "The differential diagnosis of GSDs includes the following conditions: Charcot-Marie-Tooth disease Congenital disorders of glycosylation Congenital lactic acidosis Deficiencies of phosphofructokinase Disorders of uric acid metabolism DNA depletion syndrome Duchenne muscular dystrophy Duchenne-Becker muscular dystrophy Endocardial fibroelastosis Fatty acid oxidation disorders Fructose-1-phosphate aldolase deficiency Fructose-1,6-biphosphatase deficiency Galactosemia Hyperlipoproteinemia Limb-girdle muscular dystrophy Limb-girdle muscular dystrophy Lysosome-associated membrane protein 2 deficiency Mitochondrial DNA depletion syndromes Mitochondrial myopathies Neurovisceral sphingolipidosis Niemann-Pick disease Organic acidurias Organic acidurias Polymyositis Sphingomyelinase deficiency Spinal muscular atrophy Werdnig-Hoffman disease Zellweger syndrome"
        },
        {
            "id": "article-25484_5",
            "title": "Myopathy -- Etiology",
            "content": "Channelopathies Periodic paralysis (Hypokalemic, hyperkalemic, Andersen-Tawil syndrome) Nondystrophic myotonias (p.e. paramyotonia congenita, Thomsen disease) Muscular Dystrophies [5] Dystrophinopathies (Duchenne muscular dystrophy, Becker muscular dystrophy, Intermediate phenotype) Myotonic muscular dystrophies (type 1 and type 2) Facioscapulohumeral muscular dystrophies\u00a0(type 1 and type 2) Emery-Dreifuss\u00a0muscular dystrophy Limb-girdle muscular dystrophies Oculopharyngeal muscular dystrophy Congenital muscular dystrophy (most common being LAMA2-related, collagen VI-related and alfa-dystroglycan-related) Distal myopathies"
        },
        {
            "id": "article-20747_40",
            "title": "Duchenne Muscular Dystrophy -- Differential Diagnosis -- Congenital Myotonic Dystrophies",
            "content": "This encompasses a group of inherited disorders associated with muscular dystrophy. The dystrophy is characterized by an increased severity at birth but has a benign course throughout life. There is a higher association with brain malformations. This includes diseases such as Ullrich type of muscular dystrophy, Fukuyama type of congenital muscular dystrophy, and muscular dystrophy associated with Walker-Warburg syndrome, to name a few."
        },
        {
            "id": "article-20816_1",
            "title": "Dystrophinopathies -- Continuing Education Activity",
            "content": "Objectives: Describe the presentation of Duchenne muscular dystrophy. Outline the evaluation of a patient with muscular dystrophy. Summarize the treatment options for muscular dystrophy. Outline the evaluation and management of dystrophinopathies and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes. Access free multiple choice questions on this topic."
        },
        {
            "id": "Histology_Ross_1557",
            "title": "Histology_Ross",
            "content": "Several forms of muscular dystrophy are attributed to mutations of single genes encoding several proteins of the dystrophin\u2013glycoprotein complex. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are associated with mutations that affect dystrophin expression (Fig F11.2. 2); different forms of limb FIGURE F11.2.2 \u2022 Distribution of dystrophin in a patient girdle muscular dystrophy (LGMD) are caused by muta-with Duchenne muscular dystrophy (DMD). This crosstions in the genes found on the short arm of the X chromo-section of skeletal muscle was obtain from a patient diagnosed some encoding the four different sarcoglycans, and with DMD. Slide preparation similar to Fig F11.2.1. Compare another form of congenital muscular dystrophy (CMD) is the pattern and intensity of the dystrophin distribution within caused by a mutation in the gene encoding the 2 chain of affected muscle fibers to the normal individual. This muscle shows signs of hypertrophy. Some fibers do not have"
        },
        {
            "id": "article-28132_69",
            "title": "Anatomy, Bony Pelvis and Lower Limb: Thigh Quadriceps Muscle -- Other Issues -- Duchenne Muscular Dystrophy (DMD)",
            "content": "Duchenne muscular dystrophy (DMD)\u00a0is characterized by the absence of the dystrophin protein, which is essential for muscle fiber repair. The muscular cell presents with necrotic fibers, increased intramuscular fat, and fibrosis. The quadriceps muscle loses shape and function, with diminished restorative capacity and volumes."
        },
        {
            "id": "InternalMed_Harrison_31393",
            "title": "InternalMed_Harrison",
            "content": "Glucocorticoids, administered as prednisone in a dose of 0.75 mg/kg per day, significantly slow progression of Duchenne dystrophy for up to 3 years. Some patients cannot tolerate glucocorticoid therapy; weight gain and increased risk of fractures in particular represent a significant deterrent for some boys. As in other recessively inherited dystrophies presumed to arise from loss of function of a critical muscle gene, there is optimism that Duchenne disease may benefit from novel therapies that either replace the defective gene or missing protein or implement downstream corrections (e.g., skipping mutated exons or reading through mutations that introduce stop codons). This less severe form of X-linked recessive muscular dystrophy results from allelic defects of the same gene responsible for Duchenne dystrophy. Becker muscular dystrophy is ~10 times less frequent than Duchenne."
        },
        {
            "id": "article-25401_21",
            "title": "Muscular Dystrophy -- Etiology -- X-linked inheritance:",
            "content": "Duchenne muscular dystrophy:\u00a0Caused by a dystrophin gene mutation located on the small arm of the X chromosome at the Xp21 position. [8] A spontaneous mutation occurs in a third of cases, while X-linked maternal-fetal transmission accounts for two-thirds of cases. [44] [45] This mutation results in a nonfunctional dystrophin protein,\u00a0leading to effects similar to those observed\u00a0in Becker muscular dystrophy. The age of onset is\u00a0typically around 3 to 5 years,\u00a0and the distribution of involved muscles is generalized. [42]"
        },
        {
            "id": "article-19860_5",
            "title": "Congenital Muscular Dystrophy -- Epidemiology",
            "content": "Out of all the congenital muscular dystrophies, Duchenne muscular dystrophy is the most common, and its incidence is around 1 in 3600 boys. [4] The incidence of congenital muscular dystrophies in children in population-based studies was estimated to be around 0.82/100,000 children. [5] The prevalence of specific types can also be common depending on the geographical area like Fukuyama muscular dystrophy is the most common type in Japan. [6]"
        },
        {
            "id": "article-25401_71",
            "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy",
            "content": "Facioscapulohumeral muscular dystrophy begins with weakness and atrophy of facial and shoulder girdle (scapulohumeral) muscles. [117] Limb-girdle muscular dystrophy diagnosis is confirmed by excluding\u00a0acute events causing proximal weakness, and the clinical picture, including genetic pattern, excludes Duchenne and facioscapulohumeral muscular dystrophy. [117]"
        },
        {
            "id": "Neurology_Adams_11335",
            "title": "Neurology_Adams",
            "content": "This milder dystrophy is closely related to the Duchenne type clinically, genetically, and ultrastructurally, involving the same DMD gene as in the Duchenne type. It had long been noted that mixed with the Duchenne group were relatively benign cases. In 1955, Becker and Keiner proposed that the latter be separated as a distinct entity, now called Becker muscular dystrophy. The incidence is difficult to ascertain, but it has been estimated as 3 to 6 per 100,000 male births. Like the Duchenne form, it is an X-linked disorder, practically limited to males and transmitted by females. It causes weakness and hypertrophy in the same muscles as Duchenne dystrophy, but the onset is much later (mean age: 12 years; range: 5 to 45 years). While boys with Duchenne dystrophy are usually dependent on a wheel-chair by early in the second decade, it is not uncommon for those with Becker dystrophy to walk well into adult life. In comparison to Duchenne dystrophy, those with Becker and intermediate"
        },
        {
            "id": "article-25401_25",
            "title": "Muscular Dystrophy -- Epidemiology",
            "content": "Becker muscular dystrophy is a milder form resulting from mutations in the same DMD gene. This condition affects approximately 1 in every 18,000 to 30,000 individuals worldwide,\u00a0predominantly\u00a0males.\u00a0Becker muscular dystrophy typically has a later onset and milder course than Duchenne muscular dystrophy, with individuals often able to maintain ambulation into adulthood."
        },
        {
            "id": "article-20747_39",
            "title": "Duchenne Muscular Dystrophy -- Differential Diagnosis -- Limb-Girdle Muscular Dystrophy",
            "content": "This inherited dystrophy primarily affects muscles of the hip and shoulder girdles"
        },
        {
            "id": "article-20747_37",
            "title": "Duchenne Muscular Dystrophy -- Differential Diagnosis -- Intermediate form of Muscular Dystrophy",
            "content": "Patients with this form of dystrophy have dystrophin levels between DMD and BMD."
        },
        {
            "id": "article-25401_75",
            "title": "Muscular Dystrophy -- History and Physical -- Cognitive dysfunction",
            "content": "Mild to moderate cognitive\u00a0impairment\u00a0are common but not universal. [121] Intellectual impairment in Duchenne dystrophy is common, with the average intelligence quotient (IQ) approximately\u00a01 standard deviation below the mean. [122] A moderate degree of intellectual disability causes these children to have a mean IQ of approximately 80. [123] Impairment of intellectual function appears nonprogressive, affecting verbal ability more than performance. [124] Mental retardation may occur in Becker dystrophy, but it is not as common as in Duchenne.\u00a0The central nervous system\u00a0is affected by some forms of congenital muscular dystrophy. [121] [125] Seizures and hypersomnia"
        }
    ],
    "scores": [
        16.48110008239746,
        15.113900184631348,
        14.74899959564209,
        14.731100082397461,
        14.383000373840332,
        14.37969970703125,
        14.244600296020508,
        14.185799598693848,
        14.060999870300293,
        14.024900436401367,
        13.974900245666504,
        13.817399978637695,
        13.746399879455566,
        13.730199813842773,
        13.724699974060059,
        13.716699600219727,
        13.619099617004395,
        13.567099571228027,
        13.550600051879883,
        13.516300201416016,
        13.498499870300293,
        13.462599754333496,
        13.45479965209961,
        13.445599555969238,
        13.355199813842773,
        13.223400115966797,
        13.208700180053711,
        13.18809986114502,
        13.104900360107422,
        13.100500106811523,
        13.06659984588623,
        13.036499977111816
    ]
}